Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for IDYA
| Stock Name | Ideaya Biosciences Inc |
| Ticker | IDYA(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US45166A1025 |
| LEI | 549300ULW08F62IJML11 |
Show aggregate IDYA holdings
News associated with IDYA
- IDEAYA Biosciences (NASDAQ:IDYA) Shares Up 5.6% After Analyst Upgrade
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report)’s stock price was up 5.6% on Tuesday after Royal Bank Of Canada raised their price target on the stock from $36.00 to $38.00. Royal Bank Of Canada currently has an outperform rating on the stock. IDEAYA Biosciences traded as high as $24.68 and last traded at $24.70. […] - 2025-09-11 02:13:34
- IDEAYA Biosciences Announces Positive Interim Data From Ongoing Phase 2 Trial Of Darovasertib
- (RTTNews) - IDEAYA Biosciences, Inc. (IDYA), Monday announced positive interim data from its ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma. - 2025-09-08 08:32:22
- JPMorgan Chase & Co. Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $74.00
- IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its target price increased by stock analysts at JPMorgan Chase & Co. from $72.00 to $74.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 186.49% from […] - 2025-09-05 05:35:08
- IDEAYA Biosciences (NASDAQ:IDYA) Trading Up 5.1% After Analyst Upgrade
- Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) traded up 5.1% on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $72.00 to $74.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. IDEAYA Biosciences traded as high as $26.31 and last traded at $26.78. […] - 2025-09-05 02:15:52
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $47.10 Average PT from Analysts
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average […] - 2025-09-02 03:06:51
- Sum Up The Parts: ESML Could Be Worth $50
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-12 08:44:07
- XTX Topco Ltd Acquires 17,536 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- XTX Topco Ltd grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 138.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,215 shares of the company’s stock after purchasing an additional 17,536 shares during the quarter. XTX Topco Ltd’s holdings in […] - 2025-08-08 04:40:50
- TD Asset Management Inc Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- TD Asset Management Inc decreased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 46.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,036 shares of the company’s stock after selling 30,254 shares during the period. TD Asset Management […] - 2025-08-05 04:37:20
- JPMorgan Chase & Co. Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock Price
- IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price target increased by analysts at JPMorgan Chase & Co. from $66.00 to $72.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 189.86% […] - 2025-07-30 03:06:51
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of “Moderate Buy” by Brokerages
- Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to […] - 2025-07-11 05:22:55
- LABU's Holdings Imply 58% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-10 07:59:01
- Oppenheimer Asset Management Inc. Has $189,000 Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Oppenheimer Asset Management Inc. boosted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 33.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,560 shares of the company’s stock after buying an additional 2,884 shares during the […] - 2025-07-01 04:51:00
- Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $54.27
- Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have received an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy […] - 2025-06-19 02:14:54
- Rhumbline Advisers Increases Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Rhumbline Advisers raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 9.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,437 shares of the company’s stock after acquiring an additional 10,876 shares during the period. Rhumbline Advisers’ […] - 2025-06-17 04:29:02
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 1.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 323,286 shares of the company’s stock after purchasing an additional 4,790 shares during the quarter. UBS AM a […] - 2025-06-01 05:37:01
- Legal & General Group Plc Buys 6,064 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Legal & General Group Plc boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,442 shares of the company’s stock after buying an additional 6,064 […] - 2025-04-25 05:12:49
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.58 Consensus Target Price from Brokerages
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the […] - 2025-04-23 02:32:56
- JPMorgan Chase & Co. Acquires 194,913 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- JPMorgan Chase & Co. boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 244.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 274,693 shares of the company’s stock after purchasing an additional 194,913 shares during the period. JPMorgan Chase & Co.’s holdings in IDEAYA Biosciences were worth […] - 2025-04-17 04:27:21
- Geode Capital Management LLC Has $51.12 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Geode Capital Management LLC increased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,988,681 shares of the company’s stock after purchasing an additional 43,226 shares during the […] - 2025-04-14 05:43:01
- Wellington Management Group LLP Sells 2,321 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Wellington Management Group LLP cut its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,790 shares of the company’s stock after selling 2,321 shares during the quarter. Wellington Management Group LLP’s […] - 2025-04-14 04:50:48
- Norges Bank Purchases Shares of 520,810 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Norges Bank acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 520,810 shares of the company’s stock, valued at approximately $13,385,000. Several other institutional investors and hedge funds have also added to or reduced their stakes in IDYA. UBS AM a […] - 2025-04-08 06:22:52
- Orion Portfolio Solutions LLC Reduces Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Orion Portfolio Solutions LLC reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 39.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 17,769 shares of the company’s stock after selling 11,784 shares during the period. Orion Portfolio Solutions LLC’s holdings in IDEAYA Biosciences were worth $457,000 at the end of the […] - 2025-04-08 05:02:50
- Vanguard Group Inc. Buys 282,936 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Vanguard Group Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,078,084 shares of the company’s stock after purchasing an additional 282,936 shares during the quarter. Vanguard Group Inc. owned about 0.06% of IDEAYA Biosciences worth $130,507,000 […] - 2025-04-08 04:28:47
- Mitsubishi UFJ Asset Management Co. Ltd. Sells 30,870 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Mitsubishi UFJ Asset Management Co. Ltd. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 81.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,856 shares of the company’s stock after selling 30,870 […] - 2025-04-04 05:19:12
- Charles Schwab Investment Management Inc. Acquires 23,738 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Charles Schwab Investment Management Inc. grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 712,811 shares of the company’s stock after purchasing an additional 23,738 shares during the period. Charles Schwab Investment […] - 2025-03-20 06:14:48
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Daiwa Securities Group Inc.
- Daiwa Securities Group Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 44.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,792 shares of the company’s stock after acquiring an additional 853 shares during the quarter. Daiwa Securities Group […] - 2025-03-18 05:43:16
- AlphaQuest LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- AlphaQuest LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 77.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 7,661 shares of the company’s stock after selling 26,401 shares during the period. AlphaQuest LLC’s holdings in IDEAYA Biosciences were worth $197,000 at the end of the most recent […] - 2025-03-17 06:03:03
- Victory Capital Management Inc. Buys 27,806 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Victory Capital Management Inc. increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 8.9% in the 4th quarter, Holdings Channel reports. The firm owned 341,063 shares of the company’s stock after purchasing an additional 27,806 shares during the period. Victory Capital Management Inc.’s holdings in IDEAYA Biosciences were worth $8,765,000 as of […] - 2025-03-14 05:56:54
- Assetmark Inc. Boosts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Assetmark Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 2.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 45,269 shares of the company’s stock after purchasing an additional 1,084 shares during the period. Assetmark Inc. owned about 0.05% of IDEAYA Biosciences worth […] - 2025-03-12 05:58:56
- Oppenheimer Asset Management Inc. Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
- Oppenheimer Asset Management Inc. trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,676 shares of the company’s stock after selling 3,382 shares during the quarter. […] - 2025-03-07 06:45:00
iShares MSCI World Small Cap UCITS ETF USD (Acc) IDYA holdings
| Date | Number of IDYA Shares Held | Base Market Value of IDYA Shares | Local Market Value of IDYA Shares | Change in IDYA Shares Held | Change in IDYA Base Value | Current Price per IDYA Share Held | Previous Price per IDYA Share Held |
|---|
| 2025-10-15 (Wednesday) | 58,724 | USD 1,666,587 | USD 1,666,587 | | | | |
| 2025-10-10 (Friday) | 58,364 | USD 1,531,471 | USD 1,531,471 | | | | |
| 2025-10-08 (Wednesday) | 58,364 | USD 1,566,490 | USD 1,566,490 | | | | |
| 2025-10-07 (Tuesday) | 58,364 | USD 1,571,159 | USD 1,571,159 | 240 | USD -26,670 | USD 26.92 | USD 27.49 |
| 2025-10-06 (Monday) | 58,124 | USD 1,597,829 | USD 1,597,829 | 0 | USD -8,718 | USD 27.49 | USD 27.64 |
| 2025-10-03 (Friday) | 58,124 | USD 1,606,547 | USD 1,606,547 | 0 | USD 25,574 | USD 27.64 | USD 27.2 |
| 2025-10-02 (Thursday) | 58,124 | USD 1,580,973 | USD 1,580,973 | 0 | USD -9,300 | USD 27.2 | USD 27.36 |
| 2025-10-01 (Wednesday) | 58,124 | USD 1,590,273 | USD 1,590,273 | 0 | USD 8,719 | USD 27.36 | USD 27.21 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of IDYA by Blackrock for IE00BF4RFH31
Show aggregate share trades of IDYA| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 240 | | | 26.920* | | 22.94 |
| 2025-09-08 | SELL | -480 | | | 23.390* | | 22.76 Profit of 10,927 on sale |
| 2025-08-15 | BUY | 240 | | | 24.330* | | 22.76 |
| 2025-08-07 | BUY | 714 | | | 22.410* | | 22.75 |
| 2025-07-29 | BUY | 238 | | | 24.840* | | 22.69 |
| 2025-07-14 | BUY | 480 | | | 22.580* | | 22.69 |
| 2025-06-30 | BUY | 480 | | | 21.020* | | 22.71 |
| 2025-06-25 | BUY | 720 | | | 22.010* | | 22.73 |
| 2025-06-20 | SELL | -121 | | | 21.670* | | 22.75 Profit of 2,753 on sale |
| 2025-06-12 | SELL | -968 | | | 22.280* | | 22.78 Profit of 22,047 on sale |
| 2025-06-02 | BUY | 366 | | | 21.220* | | 22.84 |
| 2025-05-28 | BUY | 244 | | | 19.560* | | 22.90 |
| 2025-05-14 | BUY | 122 | | | 17.100* | | 23.24 |
| 2025-05-13 | BUY | 244 | | | 17.450* | | 23.28 |
| 2025-05-07 | BUY | 363 | | | 17.830* | | 23.45 |
| 2025-04-28 | BUY | 121 | | | 19.750* | | 23.66 |
| 2025-04-16 | BUY | 1,586 | | | 16.180* | | 24.07 |
| 2025-04-14 | BUY | 244 | | | 17.110* | | 24.20 |
| 2025-04-08 | SELL | -246 | | | 14.500* | | 24.52 Profit of 6,033 on sale |
| 2025-04-04 | SELL | -248 | | | 14.710* | | 24.71 Profit of 6,128 on sale |
| 2025-03-28 | BUY | 1,230 | | | 17.050* | | 25.06 |
| 2025-03-12 | SELL | -246 | | | 18.600* | | 25.98 Profit of 6,392 on sale |
| 2025-03-04 | SELL | -244 | | | 18.790* | | 26.44 Profit of 6,450 on sale |
| 2025-02-26 | SELL | -488 | | | 20.750* | | 26.76 Profit of 13,058 on sale |
| 2025-02-13 | BUY | 123 | | | 20.760* | | 27.50 |
| 2025-02-12 | BUY | 492 | | | 21.950* | | 27.58 |
| 2025-01-27 | BUY | 121 | | | 23.800* | | 28.43 |
| 2025-01-23 | BUY | 121 | | | 23.290* | | 28.61 |
| 2024-12-09 | BUY | 3,492 | | | 27.730* | | 28.87 |
| 2024-12-04 | BUY | 194 | | | 28.350* | | 28.96 |
| 2024-12-03 | BUY | 291 | | | 26.660* | | 29.01 |
| 2024-11-19 | BUY | 582 | | | 25.860* | | 29.82 |
| 2024-11-18 | BUY | 192 | | | 26.190* | | 29.93 |
| 2024-11-12 | BUY | 380 | | | 30.980* | | 29.90 |
| 2024-11-11 | BUY | 96 | | | 31.980* | | 29.76 |
| 2024-11-11 | BUY | 96 | | | 31.980* | | 29.76 |
| 2024-11-07 | BUY | 475 | | | 29.990* | | 29.63 |
| 2024-11-07 | BUY | 475 | | | 29.990* | | 29.63 |
| 2024-10-23 | BUY | 190 | | | 29.500* | | 30.55 |
| 2024-10-23 | BUY | 190 | | | 29.500* | | 30.55 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of IDYA
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 159,347 | 700 | 337,972 | 47.1% |
| 2025-09-18 | 102,062 | 0 | 354,538 | 28.8% |
| 2025-09-17 | 129,233 | 0 | 282,405 | 45.8% |
| 2025-09-16 | 140,782 | 0 | 365,507 | 38.5% |
| 2025-09-15 | 180,719 | 0 | 331,985 | 54.4% |
| 2025-09-12 | 251,060 | 97 | 384,314 | 65.3% |
| 2025-09-11 | 257,937 | 0 | 806,179 | 32.0% |
| 2025-09-10 | 399,093 | 0 | 657,595 | 60.7% |
| 2025-09-09 | 540,943 | 47,428 | 1,130,110 | 47.9% |
| 2025-09-08 | 663,538 | 40,340 | 1,460,245 | 45.4% |
| 2025-09-05 | 291,425 | 501 | 857,896 | 34.0% |
| 2025-09-04 | 293,834 | 11,632 | 650,370 | 45.2% |
| 2025-09-03 | 206,414 | 0 | 498,513 | 41.4% |
| 2025-09-02 | 399,302 | 0 | 1,106,951 | 36.1% |
| 2025-08-29 | 138,381 | 0 | 240,026 | 57.7% |
| 2025-08-28 | 87,767 | 0 | 231,895 | 37.8% |
| 2025-08-27 | 76,952 | 0 | 183,706 | 41.9% |
| 2025-08-26 | 71,766 | 0 | 218,287 | 32.9% |
| 2025-08-25 | 220,761 | 0 | 315,818 | 69.9% |
| 2025-08-22 | 106,324 | 525 | 349,111 | 30.5% |
| 2025-08-21 | 183,678 | 0 | 348,674 | 52.7% |
| 2025-08-20 | 304,758 | 0 | 418,625 | 72.8% |
| 2025-08-19 | 249,340 | 0 | 466,095 | 53.5% |
| 2025-08-18 | 292,946 | 6,166 | 430,258 | 68.1% |
| 2025-08-15 | 128,237 | 0 | 249,939 | 51.3% |
| 2025-08-14 | 133,674 | 2,000 | 225,126 | 59.4% |
| 2025-08-13 | 135,358 | 0 | 258,289 | 52.4% |
| 2025-08-12 | 95,636 | 0 | 234,475 | 40.8% |
| 2025-08-11 | 185,941 | 0 | 306,491 | 60.7% |
| 2025-08-08 | 164,531 | 2,628 | 237,905 | 69.2% |
| 2025-08-07 | 138,612 | 0 | 221,914 | 62.5% |
| 2025-08-06 | 154,817 | 268 | 246,544 | 62.8% |
| 2025-08-05 | 376,434 | 4 | 488,358 | 77.1% |
| 2025-08-04 | 195,099 | 0 | 399,204 | 48.9% |
| 2025-08-01 | 200,968 | 0 | 273,780 | 73.4% |
| 2025-07-31 | 147,500 | 3,884 | 285,254 | 51.7% |
| 2025-07-30 | 324,178 | 0 | 777,671 | 41.7% |
| 2025-07-29 | 255,786 | 529 | 370,796 | 69.0% |
| 2025-07-28 | 365,885 | 0 | 971,515 | 37.7% |
| 2025-07-25 | 201,606 | 556 | 370,993 | 54.3% |
| 2025-07-24 | 467,727 | 39 | 1,117,565 | 41.9% |
| 2025-07-23 | 265,550 | 258 | 381,033 | 69.7% |
| 2025-07-22 | 139,904 | 0 | 500,681 | 27.9% |
| 2025-07-21 | 95,928 | 0 | 244,884 | 39.2% |
| 2025-07-18 | 85,255 | 0 | 126,805 | 67.2% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.